A Dual-Action Therapeutic Composition from Solanum Aethiopicum for Integrated Management of Type 2 Diabetes and Obesity
Jean Michel Kayumba
ABSTRACT
Background: Type 2 diabetes and obesity are tightly linked pandemics with shared pathophysiology and mounting global burden. Conventional pharmacotherapies frequently target single pathways and may worsen weight gain or fail to address composite metabolic risk. We developed YKD-001, a standardized therapeutic composition derived from Solanum aethiopicum L. (African eggplant) fruits, designed for simultaneous glycemic and weight control through multi-pathway actions.
Methods: Fruits of S. aethiopicum were authenticated and processed via a proprietary hydroethanolic extraction and enrichment protocol that concentrates glycoalkaloids, steroidal alkaloids, and phenolic constituents. Phytochemical profiling used HPLC-DAD and LC–MS/MS against reference markers (e.g., solamargine, solasonine, chlorogenic acid, rutin). Bioactivity was evaluated in digestive enzyme assays (α-glucosidase, α-amylase, pancreatic lipase), cellular models of glucose uptake and insulin signaling (L6 myotubes and 3T3-L1 adipocytes), and diet-induced metabolic dysfunction in rodents. Safety was assessed by in vitro cytotoxicity and acute/subacute oral toxicity. Analyses employed ANOVA with post hoc tests.
Results: The standardized extract yielded reproducible chemical fingerprints with batch-to-batch variation <10% for primary markers. YKD-001 inhibited α-glucosidase by 78%, α-amylase by 65%, and pancreatic lipase by 72% at standardized activity units, indicating concurrent attenuation of carbohydrate and lipid hydrolysis. In vivo, YKD-001 reduced fasting glucose by 35%, decreased HbA1c-equivalent markers by 28%, and produced 12% body weight loss versus baseline in obesediabetic rodent models. Cellular assays showed increased insulin-stimulated glucose uptake and enhanced AKT phosphorylation, with modest inhibition of adipogenesis and reduction in ROS. No acute toxicity was observed at limit doses; subacute administration showed no clinically meaningful changes in hematology, clinical chemistry, or histopathology.
Conclusions: YKD-001 is a dual-action, multi-target composition that integrates enzyme inhibition, insulin sensitization, and antioxidant pathways to improve glycemic control and weight outcomes. These preclinical data support clinical evaluation of YKD-001 as a safe, standardized natural product candidate for metabolic syndrome, type 2 diabetes, and obesity.
